Capricor Therapeutics Says FDA Extends PDUFA Target Action Date for BLA for Deramiocel, Investigational Cell Therapy for Duchenne Muscular Dystrophy, from August 22 to November 22

Observed price moves

• CAPR-25.09%15 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.